-
Cluster Analysis To Explore Clinical Subphenotypes Of Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). J. Rheumatol. (IF 3.9) Pub Date : 2023-09-22 Emma Rubenstein, Carla Maldini, Augusto Vaglio, Federica Bello, Jan Phillip Bremer, Frank Moosig, Paolo Bottero, Alberto Pesci, Renato Alberto Sinico, Julian Grosskreutz, Claudia Feder, David Saadoun, Giorgio Trivioli, Federica Maritati, Barbara Rewerska, Wojciech Szczeklik, Paolo Fraticelli, Giuseppe Guida, Gina Gregorini, Gianluca Moroncini, Bernhard Hellmich, Jochen Zwerina, Matthieu Resche-Rigon
Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA) could be determined by presence or absence of antineutrophil cytoplasmic antibodies (ANCA), reflecting predominant vasculitic or eosinophilic processes, respectively. This study explored whether ANCA-based clusters or other clusters can be identified in EGPA.
-
Long term prognosis of anti-melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Tsuneo Sasai, Ran Nakashima, Hideaki Tsuji, Toshiki Nakajima, Yoshitaka Imura, Yusuke Yoshida, Shintaro Hirata, Mirei Shirakashi, Ryosuke Hiwa, Koji Kitagori, Shuji Akizuki, Hajime Yoshifuji, Tsuneyo Mimori, Akio Morinobu
Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis with interstitial lung disease (DM-ILD) progresses rapidly and has a poor prognosis. Recently, we reported the efficacy of a combination therapy comprising high-dose glucocorticoids (GCs), calcineurin inhibitors (CNIs), and intravenous cyclophosphamide (IVCY) in a multicenter clinical trial (UMIN000014344). In the present
-
Features of Knee and Multi-joint Osteoarthritis by Sex and Race/Ethnicity: A Preliminary Analysis in the Johnston County Health Study. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Sherwin Novin, Carolina Alvarez, Jordan Renner, Yvonne Golightly, Amanda Nelson
To evaluate knee and multi-joint osteoarthritis (KOA and MJOA) and compare features by sex and race/ethnicity in a population-based cohort.
-
Changes in TNF inhibitor drug survival in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis over 15 years. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Ingrid Visman, Sadaf Atiqi, Maarten Boers, Jos Twisk, Michael Nurmohamed
To study changes in retention of first biologic DMARD therapy over a period of 15 years in an inception cohort of patients with Rheumatoid arthritis (RA), Psoriatic arthritis (PsA) and Ankylosing Spondylitis (AS).
-
The Journal of Rheumatology: A Strong Supporter of Pediatric Rheumatology. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Ronald M Laxer
I am very much enjoying your trip down memory lane looking back at important articles in The Journal of Rheumatology I was especially interested in your "Looking Back at the 1990s." I would like to point out an important milestone in The Journal that also took place in the 1990s, that is, the establishment of Pediatric Rheumatology as a section in The Journal.
-
Unequal Treatment: Physical Therapy Utilization in Rheumatoid Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Jennifer L Barton
The American College of Rheumatology (ACR) 2022 guidelines for nonpharmacologic management of rheumatoid arthritis (RA) include a conditional recommendation for physical therapy (PT).1 Known disparities by socioeconomic status (SES) and race and ethnicity in RA prevalence, patient-reported outcomes of function, disease activity, and access exist and persist over time.2,3.
-
Thoracic Clavicular Gout. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Zheng Liao, Li Deng, Xiaowen Luo, Zhenhua Wen
Gout is a common condition characterized by the deposition of monosodium urate (MSU) crystals in articular and nonarticular structures.1 The formation of MSU crystals has been reported in atypical locations such as the eye, nose, spine, and viscera.2.
-
Clinical improvement in early onset interstitial lung disease using rituximab in children with anti-MDA5 positive juvenile dermatomyositis. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Malki Peskin, Marilyn Mostowy, Jennifer Velez, Megan Perron, Jessica Kurian, Dawn M Wahezi
Children with juvenile dermatomyositis (JDM) and antibodies to melanoma differentiation associated gene 5 (anti-MDA5) are at increased risk of severe disease complications, including interstitial lung disease (ILD). Data regarding treatment of disease complications in this patient population is limited. In this study, we examined the disease course of children with JDM and anti-MDA5 antibodies before
-
Military Report From the Front. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Dariusz Wołodźko
there is no front line everything is war front territory of the organism under attack enemy takes control.
-
Chew on This: The Afterbite of Temporomandibular Joint Involvement in Adults With Juvenile Idiopathic Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Evelyn Victoria Rozenblyum, Mercedes Olivia Chan, Natasha Kaur Gakhal
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease that continues into adulthood in approximately 50% of patients.1 Growth considerations are unique to pediatric-onset disease and can lead to permanent joint damage.
-
Complement proteins L-ficolin and M-ficolin are increased in axial spondyloarthritis patients and decrease after TNF-inhibitor treatment. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Clara Elbæk Mistegaard, Anne Troldborg, Annette Hansen, Steffen Thiel, Anne Grethe Jurik, Rosa M Kiil, Alice A Christiansen, Berit Schiøttz-Christensen, Oliver Hendricks, Susanne Juhl Pedersen, Inge Juul Sørensen, Mikkel Østergaard, Anne Gitte Loft
We have previously reported elevated levels of the complement lectin pathway proteins L-ficolin and H-ficolin in axial spondyloarthritis (axSpA) patients compared with healthy controls. The aim of this study was to investigate these biomarkers in a cross-sectional cohort of patients suffering from low back pain (LBP). Furthermore, we aimed to investigate changes in lectin pathway protein levels after
-
The Combination of Depression and Obesity was Associated with Increased Incidence of Subsequent Total Knee Arthroplasty. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Caitlin E W Conley, David C Landy, Christian Lattermann, Joanne Borg-Stein, Jamie E Collins, Ana-Maria Vranceanu, Cale A Jacobs
Compare the incidence of total knee arthroplasty (TKA) within the first 5 years after knee OA diagnoses between matched groups of individuals with or without comorbid diagnoses of obesity and/or depression. We hypothesized that the greatest incidence of TKA within 5 years of OA diagnosis would be in the cohort of individuals with combined obesity and depression.
-
Ultrasound in the management of patients with psoriatic arthritis: systematic literature review and novel algorithms for pragmatic use. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-15 Hélène Gouze, Marina Backhaus, Peter Balint, Andrea Di Matteo, Walter Grassi, Annamaria Iagnocco, Esperanza Naredo, Richard J Wakefield, Mikkel Østergaard, Paul Emery, Maria-Antonietta D'Agostino
In 2015, the European Alliance of Associations for Rheumatology (EULAR) published recommendations for the use of imaging for the diagnosis and management of spondyloarthritis in clinical practice. These recommendations included the use of ultrasound in patients with psoriatic arthritis (PsA), but the management was not clearly distinguished from spondyloarthritis. We aimed to systematically review
-
Racial and Ethnic Distribution of Rheumatic Diseases in Health Systems of the National Patient-Centered Clinical Research Network. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-01 William Benjamin Nowell, Edward L Barnes, Shilpa Venkatachalam, Michael D Kappelman, Jeffrey R Curtis, Peter A Merkel, Dianne G Shaw, Kalen Larson, Justin Greisz, Michael D George
To evaluate the relative prevalence of 8 rheumatic and musculoskeletal diseases (RMDs) across racial/ethnic groups within the Patient-Centered Research Network (PCORnet).
-
Psoriatic Arthritis And Covid-19 - Patient Perspectives In A Large Psoriatic Arthritis Cohort. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-01 Neda Pirouzmand, Daniel Pereira, Mitchell Sutton, Ashish J Mathew, Vinod Chandran, Dafna D Gladman
To estimate the prevalence of COVID-19 infection among patients with psoriatic arthritis (PsA), understand patients' perspectives regarding their risk of COVID-19 infection, and evaluate the standard of virtual care offered during the early phases of the pandemic.
-
Cluster Analysis To Explore Clinical Subphenotypes Of Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). J. Rheumatol. (IF 3.9) Pub Date : 2023-09-01 Emma Rubenstein, Carla Maldini, Augusto Vaglio, Federica Bello, Jan Phillip Bremer, Frank Moosig, Paolo Bottero, Alberto Pesci, Renato Alberto Sinico, Julian Grosskreutz, Claudia Feder, David Saadoun, Giorgio Trivioli, Federica Maritati, Barbara Rewerska, Wojciech Szczeklik, Paolo Fraticelli, Giuseppe Guida, Gina Gregorini, Gianluca Moroncini, Bernhard Hellmich, Jochen Zwerina, Matthieu Resche-Rigon
Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA) could be determined by presence or absence of antineutrophil cytoplasmic antibodies (ANCA), reflecting predominant vasculitic or eosinophilic processes, respectively. This study explored whether ANCA-based clusters or other clusters can be identified in EGPA.
-
Advances and Controversies in Our Understanding of Guttate and Plaque Psoriasis. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-01 Kristina Callis Duffin, Sam T Hwang, James G Krueger
Acute guttate psoriasis (AGP) is considered an uncommon variant of psoriasis (PsO), characterized as a widespread eruption of erythematous, psoriasiform papules, and plaques on the trunk, extremities, and scalp. Predisposing factors include a family history of PsO, variation in the main PsO susceptibility gene HLA-Cw*0602, and previous infection with viruses or acute β-hemolytic Streptococcus A program
-
Improving Outcomes in Systemic Lupus Erythematosus: The Importance of Access to Medications. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-01 Elizabeth D Ferucci
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with the potential to affect multiple organ systems and to lead to significant morbidity and mortality. SLE disproportionately affects women and racial or ethnic minority populations, and health disparities have been described for SLE incidence, prevalence, outcomes, and mortality.1.
-
Safe Treatment With Secukinumab in a Patient With Axial Spondyloarthritis and a History of a Leishmania donovani Infection. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-01 Clementina López-Medina, Antonio Doblas, Alejandro Escudero-Contreras, Eduardo Collantes-Estévez
Infections during treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) are some of the most frequent adverse events in patients with axial spondyloarthritis (axSpA) and with rheumatic diseases in general. We report a case of a 41-year-old White male with axSpA who developed a Leishmania donovani infection while under treatment with adalimumab (ADA).
-
The Prognostic Potential of End-Stage Knee Osteoarthritis and its Components to Predict Knee Replacement: Data from the Osteoarthritis Initiative. J. Rheumatol. (IF 3.9) Pub Date : 2023-09-01 Jeffrey B Driban, Bing Lu, Klaus Flechsenhar, Grace H Lo, Timothy E McAlindon
We aimed to determine how two definitions of end-stage knee osteoarthritis (esKOA) and each component (knee symptoms, persistent knee pain, radiographic severity, and presence of limited mobility or instability) related to future knee replacement (KR).
-
Multiple Aneurysms in Granulomatosis With Polyangiitis. J. Rheumatol. (IF 3.9) Pub Date : 2023-08-15 Eisuke Takamasu, So Hattori, Naoto Yokogawa, Kota Shimada
Systemic multiple aneurysms are rare findings in granulomatosis with polyangiitis (GPA).1 A 66-year-old woman presented with generalized, subcutaneous nodules and a right leg ulcer of 1-month duration.
-
Screening/referral strategies for the early recognition of psoriatic arthritis (PsA) among patients with psoriasis: results of a GRAPPA survey. J. Rheumatol. (IF 3.9) Pub Date : 2023-08-15 Kaiyang Song, Lihi Eder, Oliver FitzGerald, Niti Goel, Philip S Helliwell, Arnon Katz, Joseph F Merola, Cheryl F Rosen, Laura Coates, Denis Poddubnyy
This study aimed to explore the experiences of dermatologists and rheumatologists in the early recognition of psoriatic arthritis (PsA) and to identify potential improvements to the current shared-care model.
-
Industry-Sponsored Research Funding to Rheumatologists in the United States Between 2014 and 2022. J. Rheumatol. (IF 3.9) Pub Date : 2023-08-15 Anju Murayama
Rheumatologists are responsible for conducting research on, managing, and treating major autoimmune diseases (AIDs) such as rheumatoid arthritis (RA), systemic lupus erythematosus, and psoriasis. AIDs afflict up to 23.5 million people in the United States.
-
Symptom Appraisal and Help-seeking among Patients with Autoimmune Rheumatic Diseases: A Qualitative Study. J. Rheumatol. (IF 3.9) Pub Date : 2023-08-15 Ling Xiang, Sungwon Yoon, Andrea H L Low, Ying Ying Leung, Warren Fong, Tang Ching Lau, Dow Rhoon Koh, Julian Thumboo
Long diagnostic delay remains an unsolved problem in many autoimmune rheumatic diseases (ARDs). One of the major contributing factors is poor symptom appraisal and the resulting delayed help-seeking by patients themselves. We thus aimed to understand the experience of symptom appraisal and help-seeking among patients with ARDs in a multi-ethnic urban Asian population and to explore its influencing
-
Complementing What We Know About Systemic Lupus Erythematosus Pregnancy. J. Rheumatol. (IF 3.9) Pub Date : 2023-08-15 Bonnie L Bermas, Lisa R Sammaritano
Pregnancy in women with systemic lupus erythematosus (SLE) can increase the risk of disease flare, which in turn increases adverse pregnancy outcomes. Maternal adverse pregnancy outcomes include hypertensive disorders, increased cesarean deliveries, and death, whereas fetal adverse outcomes include fetal loss and death, preterm delivery, and intrauterine growth restriction (IUGR).1.
-
GRAPPA 2022 Trainee Symposium: A Summary of Oral and Poster Presentations. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-15 M Elaine Husni, Raminderjit Kaur, April W Armstrong, Lihi Eder
One of the highlights of the 2022 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting was the trainee symposium. Dermatology and rheumatology trainees presented their research related to psoriasis and psoriatic arthritis. This report briefly reviews 5 oral presentations and 15 posters that were selected for this annual meeting. Topics include basic/translational
-
Young-GRAPPA (Y-GRAPPA) at the GRAPPA 2022 Annual Meeting: One Year in Y-GRAPPA. Where Do We Stand, Where Do We Go? J. Rheumatol. (IF 3.9) Pub Date : 2023-07-15 Gizem Ayan, Roxana Coras, Rachel Grynszpan, Sebastián Herrera, Hannah Jethwa, Hanna J Johnsson, Dimitri L F Silva, Leonieke van Mens, Michelle L M Mulder, David Simon, Arani Vivekanantham, Fabian Proft
Young-GRAPPA (Y-GRAPPA) was introduced at the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting. Here we present the 1-year progress of Y-GRAPPA and future plans of this enthusiastic group of young clinicians and early career researchers interested in psoriasis and psoriatic arthritis.
-
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual Meeting. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-15 Melissa P Zundell, Michael J Woodbury, Kathryn Lee, Lourdes M Perez-Chada, April W Armstrong, Vibeke Strand, Joseph F Merola, Alice B Gottlieb
The International Dermatology Outcome Measures (IDEOM) organization presented an update on its progress related to patient-centered outcome measures for psoriasis (PsO) and psoriatic arthritis (PsA) at the 2022 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Musculoskeletal (MSK) Symptoms working group presented an update on the development
-
Factors associated with residual disease in axial spondyloarthritis: results from a clinical practice registry. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-15 Casper Webers, Annelies Boonen, Harald E Vonkeman, Astrid van Tubergen
To explore residual disease, defined as substantial symptoms and disease burden despite a remission/low disease activity (described as 'LDA') state, in patients with axial spondyloarthritis (axSpA) and to determine which factors are associated with residual disease.
-
Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis Receiving Tofacitinib. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-15 Christina Charles-Schoeman, Craig Hyde, Shunjie Guan, Neil Parikh, Jennifer Wang, Ani Shahbazian, Lori Stockert, John Andrews
This post hoc analysis investigated the relationship between paraoxonase-1 (PON1) genotype and activity, and risk of major adverse cardiovascular events (MACE) and malignancies in tofacitinib rheumatoid arthritis (RA) clinical studies.
-
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-15 Nicolino Ruperto, Daniel J Lovell, Alberto Berman, Jordi Anton, Diego Oscar Viola, Bernard Lauwerys, Maria Elena Rama, John Bohnsack, Johannes Breedt, Michel Fischbach, Thomas Lutz, Kirsten Minden, Mahmood Ally, Nadina Rubio-Pérez, Elisabeth Gervais, Riana Van Zyl, Robert Wong, Margarita Askelson, Alberto Martini, Hermine I Brunner
Describe the efficacy and safety data of children with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with abatacept + methotrexate (MTX) or abatacept monotherapy when prior MTX use was either ineffective or not tolerated.
-
Obesity represents a persisting health issue in axial spondyloarthritis, particularly affecting socially disadvantaged patients. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-15 Raphael Micheroli, Sangeeta Bhatia, Enriqueta Vallejo-Yagüe, Andrea Michelle Burden, Burkhard Möller, Michael J Nissen, Diego Kyburz, Seraphina Kissling, Oliver Distler, Caroline Ospelt, Adrian Ciurea
Obesity is an important comorbidity in axial spondyloarthritis (axSpA). However, the prevalence of obesity in axSpA compared with the general population and associated socioeconomic factors remain unknown.
-
Developing Ultrasound Measures for the Early Diagnosis of Psoriatic Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-15 Gurjit S Kaeley, Lihi Eder, Sibel Z Aydin
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) ultrasound (US) steering committee provided an update at GRAPPA's 2022 annual meeting on activities to enable earlier diagnosis of psoriatic arthritis. An update of the Diagnostic Ultrasound Enthesitis Tool (DUET) study included preliminary reliability results for US enthesitis elementary lesions. Common scanning pitfalls
-
Sex in the Time of COVID-19. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-15 Mark Harrison
Time passes swiftly and is irrecoverable. In Love in the Time of Cholera, Gabriel García Márquez uses cholera as an analogy for the physical and emotional burdens caused by longing and lovesickness. Just as Florentino Ariza suffers physical and emotional pains from his longing for Fermina Daza, as one might suffer from a disease like cholera, in this issue, Katz and Ye tell a story of longing for equal
-
GRAPPA 2021 Treatment Recommendations for Psoriatic Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Enrique R Soriano, Laura C Coates, Arthur Kavanaugh
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 annual meeting, the recently published new GRAPPA recommendations were presented and their unique characteristics highlighted, including their truly international approach, the inclusion of patient views from the very beginning, the representation by both rheumatologists and dermatologists, consideration of
-
Project Highlights From the GRAPPA 2022 Annual Meeting: Education Initiatives and Axial Involvement in Psoriatic Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Murat Torgutalp, Dafna D Gladman, Oliver FitzGerald, Philip J Mease, Denis Poddubnyy
A core mission of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) is to provide education about psoriasis and psoriatic arthritis globally. This is a multifaceted endeavor involving in-person and virtual lectures, discussions, podcasts, and archived videos directed toward clinicians and researchers who are involved with psoriatic disease (PsD) care. In partnership
-
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Ying-Ying Leung, William Tillett, Maarten de Wit, Ana-Maria Orbai, Laura C Coates, Oliver FitzGerald, Philip S Helliwell, Vibeke Strand, Philip J Mease, Niti Goel, Robin Christensen, Joseph F Merola, Christine A Lindsay, Alexis Ogdie, Laure Gossec, Dafna D Gladman
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group-comprising rheumatologists, dermatologists, methodologists, and patient research partners-provided updates at the GRAPPA 2022 annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were
-
Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics? J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Rosario Agüero, Michael J Woodbury, Kathryn Lee, Hanna J Johnsson, Joseph F Merola, April W Armstrong
Interleukin (IL)-17 and IL-23 inhibitors are both approved for the treatment of moderate-to-severe plaque psoriasis (PsO), as well as psoriatic arthritis (PsA). In the absence of head-to-head studies, it is not clear which agent is better suited to treat patients with moderate-to-severe PsO and mild PsA. During the 2022 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
-
Identification of Psoriatic Arthritis in Patients With Psoriasis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Laura C Coates, Lihi Eder, Denis Poddubnyy, Cheryl F Rosen
People with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Screening patients with PsO for PsA may be helpful in diagnosing PsA early. Dermatologists play a role in assessing their patients with PsO for musculoskeletal symptoms and referring them to a rheumatologist for diagnosis and treatment.
-
GRAPPA 2022 Patient Research Partners Network Update: Managing Growth. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Ingrid Steinkoenig, Niti Goel, Arnon Katz
Seven patient research partners (PRPs) attended the 2022 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in person, the first in-person annual meeting since the start of the coronavirus disease 2019 (COVID-19) pandemic. The GRAPPA PRP Network remains engaged and committed to providing dedicated voices supporting delivery of the GRAPPA mission. This
-
Is Axial Psoriatic Arthritis the Same as Ankylosing Spondylitis With Psoriasis: A Debate. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Laura C Coates, Atul Deodhar
During the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 conference, Drs. Laura Coates and Atul Deodhar debated whether axial psoriatic arthritis (axPsA) is the same as ankylosing spondylitis (AS) with psoriasis. Dr. Coates argued that AS represents a spectrum of disease and that axPsA can be considered within that spectrum. Dr. Deodhar argued that axPsA and AS
-
Advances in the Evaluation of Peripheral Enthesitis by Magnetic Resonance Imaging in Patients With Psoriatic Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Mikkel Østergaard, Walter P Maksymowych
Enthesitis is a key disease manifestation in patients with psoriatic arthritis (PsA) that considerably contributes to pain, lower physical function, and reduced quality of life. Clinical assessment of enthesitis lacks sensitivity and specificity, and therefore better methods are urgently needed. Magnetic resonance imaging (MRI) allows detailed assessment of the components of enthesitis, and consensus-based
-
Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 Annual Meeting. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Alice B Gottlieb, April W Armstrong, Oliver FitzGerald, Dafna D Gladman
The 2022 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held from July 14 to 17, 2022, in New York City, New York, USA, and was attended by 420 rheumatologists, dermatologists, basic scientists, allied health professionals, patient research partners, and industry partners from 31 countries. A GRAPPA executive retreat, a Trainee Symposium, and
-
GRAPPA 2021 Pilot Grant Award Reports. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-07 Fazira R Kasiem, Daisuke Yamada, Josefina Marin, Marijn Vis, William Tillett, Samuel T Hwang, Enrique R Soriano, Oliver FitzGerald, April W Armstrong
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) pilot grant awards help support young researchers starting their careers while also encouraging them to develop a focus on psoriatic disease. In this brief report, winners of the 2020 and 2021 awards present the results of their pilot projects.
-
Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Eveline Y Wu, Melissa Oliver, Joshua Scheck, Sivia Lapidus, Ummusen Kaya Akca, Shima Yasin, Sara M Stern, Antonella Insalaco, Manuela Pardeo, Gabriele Simonini, Edoardo Marrani, Xing Wang, Bin Huang, Leonard K Kovalick, Natalie Rosenwasser, Gabriel Casselman, Adriel Liau, Yurong Shao, Claire Yang, Doaa Mosad Mosa, Lori Tucker, Hermann Girschick, Ronald M Laxer, Jonathan D Akikusa, Christian Hedrich
Prospective comparative effectiveness research (CER) in chronic nonbacterial osteomyelitis (CNO) is lacking. Our objectives were:1) determine the use and safety of each consensus treatment plan (CTP) regimen for CNO, 2) assess the feasibility of using chronic nonbacterial osteomyelitis international registry (CHOIR) data for CER, and 3) develop and validate a CNO clinical disease activity score (CDAS)
-
Dr. Gottlieb et al reply. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Chloe Gottlieb, Roberta A Berard, Deborah M Levy, Eric Fortin
We thank the author for their reply1 and appreciate the approach of having clear terminology and standard definitions within clinical practice guidelines or recommendations, that are applicable across specialist groups. A definition of controlled anterior uveitis or quiescent disease is important for treatment decisions, particularly when classifying a patient's disease as failing current therapy and
-
Dr. Kostadinova et al reply. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Lenche Kostadinova, Alyssa Lange, Sofi Damjanovska, Ibtissam Gad, Sameena Syed, Husna Siddiqui, Patrick Yousif, Corinne M Kowal, Carey Shive, Christopher Burant, Nora Singer, Taissa Bej, Sadeer Al-Kindi, Brigid Wilson, Maya Mattar, David A Zidar, Donald D Anthony
We appreciate the interest of Wang et al1 in our recently published dataset.2 We would like to clarify some details pertaining to the points made in their letter.1.
-
Postpartum depression in reproductive-age women with and without rheumatic disease: a population-based matched cohort study. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Divya Shridharmurthy, Kate L Lapane, Anthony Nunes, Jonggyu Baek, Michael H Weisman, Jonathan Kay, Shao-Hsien Liu
To examine postpartum depression (PPD) among women with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), or rheumatoid arthritis (RA), in comparison with a matched population without rheumatic diseases (RD).
-
Validating the FRAX Score in a US Population-Based Study of Patients with Rheumatoid Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Jehan Mousa, Madeline N Peterson, Cynthia S Crowson, Sara J Achenbach, Elizabeth J Atkinson, Shreyasee Amin, Sundeep Khosla, John M Davis, Elena Myasoedova
The FRAX algorithm for risk prediction of major osteoporotic fractures and hip fractures accounts for several risk factors, including rheumatoid arthritis (RA), as individuals with RA have an excess burden of fractures. FRAX has not been validated in population-based RA cohorts in the US. We aimed to determine the accuracy of FRAX risk predictions for individuals with RA in the US.
-
Clinically established temporomandibular involvement in adults with juvenile idiopathic arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Willemijn F C de Sonnaville, Caroline M Speksnijder, Nicolaas P A Zuithoff, Marloes W Heijstek, Nico W Wulffraat, Michel H Steenks, Antoine J W P Rosenberg
To study clinical variables defining temporomandibular function in adults with juvenile idiopathic arthritis (JIA) and healthy controls.
-
Measuring what matters: a qualitative study of the relevance and clinical utility of PROMIS® surveys in systemic lupus erythematosus. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Shanthini Kasturi, Emily L Ahearn, Adena Batterman, Roberta Horton, Juliette Kleinman, Jillian Rose-Smith, Amy M LeClair, Lisa A Mandl
To evaluate the relevance and clinical utility of Patient-Reported Outcomes Measurement Information System (PROMIS®) surveys in patients with systemic lupus erythematosus (SLE).
-
Screening for anxiety in patients with inflammatory arthritis using the multidimensional health assessment questionnaire (MDHAQ). J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Sadia Tasnim Islam, Joseph Descallar, David Martens, Geraldine Hassett, Kathryn Alleyne Gibson
To analyse the Multidimensional Health Assessment Questionnaire (MDHAQ) in screening for anxiety in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), in comparison to the Hospital Anxiety and Depression Scale (HADS) as the reference standard.
-
Type I Interferons in autoimmunity: implications in clinical phenotypes and treatment response. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Ana Carolina Londe, Ruth Fernandez Ruiz, Paulo Rogerio Julio, Simone Appenzeller, Timothy B Niewold
Type I interferon (IFN-I) is thought to play a role in many systemic autoimmune diseases. IFN-I pathway activation is associated with pathogenic features, including the presence of autoantibodies and clinical phenotypes such as more severe disease with increased disease activity and damage. We will review the role and potential drivers of IFN-I dysregulation in five prototypic autoimmune diseases:
-
Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the New Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Medha Barbhaiya, Maxime Taghavi, Stephane Zuily, Vinicius Domingues, Eugenia Yupei Chock, Maria G Tektonidou, Doruk Erkan, Surya V Seshan
Antiphospholipid antibody (aPL) nephropathy (aPL-N) can be challenging to recognize due to lack of established classification or diagnostic criteria. As part of efforts to develop new antiphospholipid syndrome (APS) classification criteria (CC), the APS CC Renal Pathology subcommittee aimed to better characterize the entity of aPL-N.
-
The Relationship Between Red Cell Distribution Width, Absolute Lymphocyte Count, and Rheumatoid Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Gang Wang, Zhichun Liu
We read with interest the recent publication by Lange and colleagues on the red cell distribution width (RDW) and absolute lymphocyte count (ALC) associated with biomarkers of inflammation and subsequent mortality in rheumatoid arthritis (RA).1 The authors concluded that RDW and ALC before disease-modifying antirheumatic drug (DMARD) therapy are associated with biomarkers of monocyte/macrophage inflammation
-
Why Do We Treat? Defining Disease Control in Juvenile Idiopathic Arthritis-Associated Uveitis. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Ameenat Lola Solebo
In a recent issue of The Journal of Rheumatology, Berard et al1 reported on the development of the Canadian recommendations for the screening, monitoring, and treatment of uveitis associated with juvenile idiopathic arthritis ( JIA).1 The guidance from this national multidisciplinary JIA-associated uveitis working group had a welcome and necessary focus on the importance of disease control but omitted
-
Assessing Serious Infections in Children Exposed In Utero to Ustekinumab. J. Rheumatol. (IF 3.9) Pub Date : 2023-07-01 Jonah H Gorodensky, Sasha Bernatsky, Waqqas Afif, Yvan St-Pierre, Kristian B Filion, Évelyne Vinet
Chronic inflammatory conditions, including inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA), have a high burden among women of reproductive age. There has been significant interest in finding safe ways of controlling disease activity during pregnancy without adversely affecting the pregnancy or offspring.
-
Medication cost concerns and disparities in patient-reported outcomes among a multiethnic cohort of patients with lupus. J. Rheumatol. (IF 3.9) Pub Date : 2023-06-15 Alfredo Aguirre,Kimberly DeQuattro,Steven Shiboski,Patricia Katz,Kurt J Greenlund,Kamil E Barbour,Caroline Gordon,Cristina Lanata,Lindsey Criswel,Maria Dall'Era,Jinoos Yazdany
OBJECTIVE Concerns about the affordability of medications are common in systemic lupus erythematosus (SLE), but the relationship between medication cost concerns and health outcomes is poorly understood. We assessed the association of self-reported medication cost concerns and patient-reported outcomes (PROs) in a multiethnic lupus cohort. METHODS The California Lupus Epidemiology Study is a cohort
-
The Effect of COVID-19 on Medication Adherence in a Rheumatoid Arthritis (BRAGGSS) and Psoriatic Arthritis (OUTPASS) UK Cohort. J. Rheumatol. (IF 3.9) Pub Date : 2023-06-15 Philippa D K Curry,Hector Chinoy,Meghna Jani,Darren Plant,Kimmie L Hyrich,Ann W Morgan,A G Wilson,John D Isaacs,Andrew P Morris,Anne Barton,James Bluett
Suboptimal treatment adherence has been reported in patients with arthritic diseases; is associated with psychological factors, including anxiety; and correlates with future treatment response.1,2 During the coronavirus disease 2019 (COVID-19) pandemic, patients who identified as clinically extremely vulnerable, including people prescribed ≥ 2 immunosuppressives, were advised to shield and continue
-
Association Between HLA Alleles and Autoantibodies in Dermatomyositis Defined by Sarcoplasmic Expression of Myxovirus Resistance Protein A. J. Rheumatol. (IF 3.9) Pub Date : 2023-06-15 Munenori Oyama,Yuko Ohnuki,Akinori Uruha,Yoshihiko Saito,Yukako Nishimori,Shingo Suzuki,Michio Inoue,Jantima Tanboon,Naoko Okiyama,Takashi Shiina,Ichizo Nishino,Shigeaki Suzuki
OBJECTIVE The diagnosis in the studies analyzing HLA of dermatomyositis (DM) was based on a combined clinical category of polymyositis/DM. This retrospective study investigated the associations of HLA with 5 DM-specific autoantibodies in Japanese patients diagnosed by muscle pathology. METHODS We diagnosed Japanese patients with DM based on sarcoplasmic expression of myxovirus resistance protein A